WARPTECHNEWS · LAB
HomeAIBusinessTechArchive
WARPTECH LAB NEWS

Warptech Lab News aggrega le notizie più rilevanti da oltre 700 fonti internazionali, con classificazione AI, TL;DR sintetici e timeline cluster su singole storie.

Navigazione

  • Home
  • Archivio
  • Editor's Brief
  • Cerca
  • Il tuo account
  • Newsletter tech/AI

Informazioni legali

  • Privacy Policy
  • Termini di servizio
  • Cookie Policy

© 2026 Sparktech S.R.L. — Tutti i diritti riservati. Sito gestito e manutenuto da Sparktech S.R.L.

Sede legale: Corso Libertà 55, 13100 Vercelli (VC), Italia · P.IVA / C.F. 02835910023 · Contatti: admin@warptechlab.com

Home
Storia in 2 fonti

Galderma gets CRL for anti-wrinkle drug; Kimball buys CDMO for $103M

Biopharma manufacturing briefs: Galderma's CRL for relabotulinumtoxinA, Kimball's $103M CDMO buy, and more.

Raccontata dafiercepharma.comendpoints.news

Confronto fonti

2 prospettive sulla stessa storia
AI · summaries
endpoints.newsStai leggendo20 h fa

Galderma gets CRL for anti-wrinkle drug; Kimball buys CDMO for $103M

Biopharma manufacturing briefs: Galderma's CRL for relabotulinumtoxinA, Kimball's $103M CDMO buy, and more.

originale
fiercepharma.com1 g fa

Kimball lays out $103M to bolster life sciences CDMO footprint across Europe, India

On a quest to bolster its life-sci contracting bona fides, self-described “multifaceted manufacturer” Kimball Electronics is going down the path of M&A.  | On a quest to bolster its life-sci contracting bona fides,…

Leggi questa versione → originale

Timeline cronologica

  1. mercoledì 1 luglio 2026·fiercepharma.com

    Kimball lays out $103M to bolster life sciences CDMO footprint across Europe, India

    On a quest to bolster its life-sci contracting bona fides, self-described “multifaceted manufacturer” Kimball Electronics is going down the path of M&A.  | On a quest to bolster…

  2. giovedì 2 luglio 2026·endpoints.news

    Galderma gets CRL for anti-wrinkle drug; Kimball buys CDMO for $103M

    Biopharma manufacturing briefs: Galderma's CRL for relabotulinumtoxinA, Kimball's $103M CDMO buy, and more.